| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 42 |
| 1 | NIVOLUMAB | 25 |
| 2 | CARBOPLATIN | 17 |
| 3 | PEMETREXED DISODIUM | 16 |
| 4 | IPILIMUMAB | 15 |
| 5 | PEMETREXED | 14 |
| 6 | DENOSUMAB | 9 |
| 7 | DEXAMETHASONE | 9 |
| 8 | DEXAMETHASONE 1.5 MG | 9 |
| 9 | PREGABALIN | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIVOLUMAB AND RELATLIMAB-RMBW | 1 | 0.0019 |
| 1 | CEFPODOXIME PROXETIL | 1 | 0.0010 |
| 2 | AVELUMAB | 4 | 0.0010 |
| 3 | CEMIPLIMAB-RWLC | 2 | 0.0010 |
| 4 | TALIMOGENE LAHERPAREPVEC | 1 | 0.0006 |
| 5 | CALCIPOTRIENE | 2 | 0.0006 |
| 6 | PIPERACILLIN AND TAZOBACTAM | 6 | 0.0005 |
| 7 | PEMETREXED DISODIUM | 16 | 0.0004 |
| 8 | FENTANYL CITRATE | 7 | 0.0004 |
| 9 | PEMBROLIZUMAB | 42 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 73 | 0.0007 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 15 | 0.0003 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 6 | 0.0003 |
| 4 | Vitamin D Analog [EPC] | 2 | 0.0001 |
| 5 | Platinum-based Drug [EPC] | 24 | 0.0001 |
| 6 | Provitamin D2 Compound [EPC] | 2 | 0.0001 |
| 7 | Interleukin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 8 | HER2/neu Receptor Antagonist [EPC] | 4 | 0.0001 |
| 9 | RANK Ligand Inhibitor [EPC] | 9 | 0.0000 |